{"organizations": [], "uuid": "b4f06b0dffa3f5d50a52cb3fad3609366943518f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180124.html", "section_title": "Archive News &amp; Video for Wednesday, 24 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-exalenz-bioscience-announces-posit/brief-exalenz-bioscience-announces-positive-clinical-trial-results-the-diagnosis-of-clinically-significant-portal-hypertension-in-nash-patients-idUSASB0C22Q", "country": "US", "domain_rank": 408, "title": "BRIEF-Exalenz Bioscience Announces Positive Clinical Trial Results The Diagnosis Of Clinically Significant Portal Hypertension In Nash Patients", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.815, "site_type": "news", "published": "2018-01-24T21:38:00.000+02:00", "replies_count": 0, "uuid": "b4f06b0dffa3f5d50a52cb3fad3609366943518f"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-exalenz-bioscience-announces-posit/brief-exalenz-bioscience-announces-positive-clinical-trial-results-the-diagnosis-of-clinically-significant-portal-hypertension-in-nash-patients-idUSASB0C22Q", "ord_in_thread": 0, "title": "BRIEF-Exalenz Bioscience Announces Positive Clinical Trial Results The Diagnosis Of Clinically Significant Portal Hypertension In Nash Patients", "locations": [], "entities": {"persons": [{"name": "nash", "sentiment": "neutral"}], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "neutral"}, {"name": "exalenz bioscience ltd", "sentiment": "neutral"}, {"name": "eikon", "sentiment": "none"}, {"name": "nash", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 24 (Reuters) - Exalenz Bioscience Ltd:\n* EXALENZ BIOSCIENCE ANNOUNCES POSITIVE CLINICAL TRIAL RESULTS FOR THE DIAGNOSIS OF CLINICALLY SIGNIFICANT PORTAL HYPERTENSION IN NASH PATIENTS\n* EXALENZ BIOSCIENCE ANNOUNCES POSITIVE CLINICAL TRIAL RESULTS FOR THE DIAGNOSIS OF CLINICALLY SIGNIFICANT PORTAL HYPERTENSION IN NASH PATIENTS\n* EXALENZ BIOSCIENCE LTD - A PRELIMINARY MODEL TO DETECT CSPH USING MBT WAS DEVELOPED WITH AN AREA UNDER RECEIVER OPERATOR CURVE (AUROC) OF 0.88\n* EXALENZ BIOSCIENCE LTD - POTENTIAL 2020 ENTRY TO AN ADDRESSABLE U.S. MARKET OF MILLIONS OF NASH PATIENTS Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-24T21:38:00.000+02:00", "crawled": "2018-01-25T13:28:33.000+02:00", "highlightTitle": ""}